New registry aims to track COVID-19 outcomes for IBD patients

A soon-to-be published study in Gastroenterology found a common therapy for inflammatory bowel disease may be associated with more severe cases of COVID-19.

Researchers from New York City-based Icahn School of Medicine at Mount Sinai and Chapel Hill-based University of North Carolina School of Medicine established a joint IBD and COVID-19 registry to track how COVID-19 is affecting IBD patients. The registry currently has 528 patients from 33 countries.

Increased age, comorbidities and corticosteroids are all associated with IBD patients with severe cases of COVID-19. However, TNF antagonist therapies did not appear to be connected with severe COVID-19.

Erica Brenna, MD, a pediatric gastroenterology fellow at Chapel Hill-based UNC Children's Hospital, commented on the registry, saying: "We established the registry to better characterize the clinical course of COVID-19 within the IBD patient population and evaluate the association between demographics, clinical characteristics, and IBD treatments on COVID-19 outcomes."

More articles on surgery centers:
4 COVID-19 supply considerations for ASCs
5 hospitals, health systems opening or planning ASCs
ASCs reopening to patients: Check these 7 boxes

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers